관해 상태인 크론병 환자에서 Saccharomyces Boulardii 복용 후 Crohn's Disease Activity Index의 변화: 단일 기관 후향적 연구
Changes in the Crohn’s Disease Activity Index and Safety of Administering Saccharomyces Boulardii in Patients with Crohn’s Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study
오규만, 문원, 서광일, 정경원, 김재현, 김성은, 박무인, 박선자,
소속 상세정보
오규만 ( Oh Gyu-Man )
Kosin University College of Medicine Department of Internal Medicine
문원 ( Moon Won )
Kosin University College of Medicine Department of Internal Medicine
서광일 ( Seo Kwang-Il )
Kosin University College of Medicine Department of Internal Medicine
정경원 ( Jung Kyoung-Won )
Kosin University College of Medicine Department of Internal Medicine
김재현 ( Kim Jae-Hyun )
Kosin University College of Medicine Department of Internal Medicine
김성은 ( Kim Sung-Eun )
Kosin University College of Medicine Department of Internal Medicine
박무인 ( Park Moo-In )
Kosin University College of Medicine Department of Internal Medicine
박선자 ( Park Seun-Ja )
Kosin University College of Medicine Department of Internal Medicine
Abstract
Background/Aims: Crohn’s disease (CD) is characterized by uncontrolled inflammation of the intestine. Saccharomyces boulardii (S. boulardii), a probiotic, stabilizes the intestinal wall. This study examined the changes in the CD activity index (CDAI) after taking S. boulardii in patients with CD in clinical remission.
Methods: In this single hospital-based retrospective cohort study, the medical records of CD patients in clinical remission, who had received S. boulardii for more than 6 months, were reviewed. The CDAI, BMI, and serum levels of hemoglobin (Hb), ferritin, iron, vitamin B12, folate, total protein, albumin, total cholesterol, CRP, and fecal calprotectin (FC) between the initiation and the 6th month were compared. The timing and reasons for the discontinuation were also investigated.
Results: One hundred and fifty-four patients were included, and 92 patients, who received for more than 6 months, were analyzed. The changes in CDAI, BMI, Hb, and total cholesterol were significant as follows: CDAI from 38.52 to 30.53 (p<0.01), BMI (kg/m2 ) from 23.38 to 23.97 (p<0.01), Hb (g/dL) from 13.73 to 14.03 (p<0.01), and total cholesterol (mg/dL) from 154.9 to 161.5 (p<0.01). On the other hand, the changes in FC, CRP, ferritin, vitamin B12, folate, total protein, and albumin were not statistically significant. Only one patient stopped due to a flare-up, but this was not believed to be related to the drug.
Conclusions: In patients with CD in remission, S. boulardii appears to improve the CDAI, BMI, serum Hb, and total cholesterol level without safety issues. Further randomized controlled studies will be needed.
키워드
Inflammatory bowel diseases; Crohn disease; Probiotics; Saccharomyces boulardii
원문 및 링크아웃 정보
등재저널 정보